Palatin Technologies, Inc.(NYSE Amex Equities : PTN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -0.75% | 85.85 | 1.3% | $1342.18m | |
| AMGN | Amgen Inc. | 0.00% | 201.56 | 1.2% | $603.80m | |
| GILD | Gilead Sciences, Inc. | 0.00% | 68.25 | 0.9% | $535.10m | |
| LOXO | Loxo Oncology Inc | -0.03% | 233.70 | 12.7% | $517.58m | |
| BIIB | Biogen Inc. | -0.51% | 337.22 | 1.3% | $412.55m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.79% | 188.40 | 1.9% | $324.00m | |
| ILMN | Illumina, Inc. | 0.53% | 303.89 | 3.5% | $304.82m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.06% | 401.44 | 2.6% | $301.11m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.92% | 118.08 | 2.0% | $225.36m | |
| EXAS | Exact Sciences Corporation | 4.79% | 79.71 | 25.3% | $149.33m | |
| A | Agilent Technologies, Inc. | 0.45% | 71.64 | 1.5% | $147.28m | |
| INCY | Incyte Corporation | 2.23% | 76.88 | 2.5% | $147.19m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.30% | 118.72 | 15.4% | $129.31m | |
| LGND | Ligand Pharmaceuticals Incorporated | -1.00% | 111.78 | 23.1% | $119.93m | |
| NBIX | Neurocrine Biosciences, Inc. | -2.15% | 89.32 | 5.1% | $95.56m |
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.